In a nutshell This study compared the safety and effectiveness of BEAM (carmustine, etoposide, cytarabine, melphalan) and FEAM (fotemustine instead of carmustine) chemotherapy regimens in patients with Hodgkin's lymphoma. This study concluded that these regimens are similarly effective, but FEAM was associated with more severe side effects. Some...
Read More
In a nutshell This study aimed to analyse the side effects associated with brentuximab vedotin (BV; Adcetris) treatment for patients with Hodgkin lymphoma (HL) who had undergone stem cell transplantation (SCT) that is now unresponsive to treatment. The main side effects identified included nerve damage, infections and low white blood cell...
Read MoreIn a nutshell This study aimed to investigate the effects of chemotherapy alone or chemotherapy plus anti-PD1 therapy in patients with relapsing/refractory (RR) Hodgkin's Lymphoma. The main finding was that anti-PD1 treatment enhances the effectiveness of chemotherapy in these patients. Some background Stem cell transplant (SCT) and...
Read More
In a nutshell This study aimed to investigate the accuracy of positron emission tomography/computed tomography (PET/CT) scanning and bone marrow biopsy (BMB) to assess bone marrow involvement (BMI) in children with newly diagnosed Hodgkin lymphoma. The main finding was that PET/CT was effective in determining BMI and biopsy should only be...
Read More
In a nutshell This study investigated the effects of increasing the initial dose of chemotherapy in patients with classical Hodgkin’s lymphoma (cHL). The main finding was that it is necessary to assess each treatment plan based on the patient’s individual disease. Some background Chemotherapy plus stem cell transplant (SCT;...
Read More
In a nutshell This study investigated the effects of pre-stem cell transplantation (pre-SCT) treatment with brentuximab vedotin (Adcetris) and bendamustine (Treanda) on patients with relapsing/refractory Hodgkin's Lymphoma (HL) following transplant. The main finding was that the drug combination was effective as a pre-SCT therapy. Some...
Read More
In a nutshell This study investigated the safety and effectiveness of stem cell transplantation (SCT) on survival in patients with unresponsive Hodgkin’s lymphoma (HL). This study found that SCT was safe and effective in patients with HL that is unresponsive to treatment. Some background Hodgkin's Lymphoma is a type of cancer of...
Read More
In a nutshell This study examined the link between the size of platelets in the blood and the development of venous thromboembolism in patients treated for newly diagnosed Hodgkin lymphoma. The main finding was that patients with larger platelets before chemotherapy were less likely to develop venous thromboembolism. Some...
Read More
In a nutshell This study investigated if pembrolizumab (Keytruda) was more effective than the standard of care in Hodgkin's lymphoma patients unresponsive to brentuximab vedotin (Adcetris). The main finding was that pembrolizumab was more effective than the standard of care in these patients Some background Hodgkin's Lymphoma is...
Read More
In a nutshell This study investigated the relationship between the primary lymph node site in Hodgkin’s lymphoma patients, their survival and course of the disease. The main finding was that patients with a primary lymph node site in the pelvis or abdomen had the worst survival of the Hodgkin’s lymphoma patients analyzed. Some...
Read MoreIn a nutshell This is the first study to look at the development of both secondary cancers and cardiovascular disease (CVD) as late side effects of Hodgkin lymphoma (HL) treatment. The study concluded that there was an increased risk of developing both a secondary cancer and CVD in patients treated before 2000. Some background...
Read More
In a nutshell This study examined whether Hodgkin lymphoma survivors were more likely to develop more aggressive forms of thyroid cancer than the general population. The authors concluded that a history of Hodgkin lymphoma was not associated with aggressive subtypes or worse outcomes of thyroid cancer. Some background Hodgkin lymphoma survivors are at...
Read More
